Allarity Therapeutics, Inc.
stenoparib
advanced ovarian cancer
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on stenoparib for advanced ovarian cancer is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“the FDA’s Fast Track designation for stenoparib underscores both the encouraging clinical benefit we have observed to date and the significant unmet medical need in this patient population.”